Clinical Trials Logo

Clinical Trial Summary

This study is designed to identify the effect of current vitreous surgery for symptomatic macular tractional maculopathy.

Characteristics of this study is as below

1. Multicenter, prospective clinical trial. (early surgical intervention vs.surgical intervention when full-thickness macular hole formation or deterioration of visual acuity occurs)

2. Non-randomized study (decision was made by patients after full explanation)

3. After 1 year follow up, functional change(visual acuity)and anatomical change would be evaluated


Clinical Trial Description

Degenerative myopia is relatively common disorder, especially in Korean, Japanese and Chinese.

Choroidal neovascularization is well-noted cause of VA deterioration, but nowadays, with improvement of diagnostic tools, such as OCT, VA deterioration from myopic tractional maculopathy is being concerned as well.

But till now, the necessity of early vitrectomy on MTM is controversial. By now some clinicians prefer conservative treatment, which means pars plana vitrectomy would be postponed till structural change such as macular hole formation is noticed. And the others prefer early vitrectomy, which means pars plana vitrectomy should be performed when the symptom begins.

In this study, investigators try to verify the validity of early vitrectomy comparing conservative treatment. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01121978
Study type Interventional
Source Seoul Retina Investigator Group
Contact Se Woong Kang, M.D.
Phone 82-2-3410-6776
Email swkang@skku.edu
Status Recruiting
Phase N/A
Start date November 2009
Completion date November 2012

See also
  Status Clinical Trial Phase
Completed NCT01423149 - Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia Phase 2
Completed NCT01968486 - Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia Phase 1
Active, not recruiting NCT05875909 - Corneal Flap Transplantation for Macular Hole Repair of High Myopia N/A
Completed NCT02806830 - Ocular Discomfort Assessment After Intravitreal Injections N/A